We found that gastric cancer tumors with a low HDS may be sensitive to GPX4 inhibitors (ML210, ML162, and 1S3R-RSL-3), survivin inhibitors (YM-155), and dasatinib (Figure 10A). This evidence concerns the gene BIRC5 and gastric cancer.